Pharmaceutical Treatment of Obesity

Gl, Blackburn; Miller, Deborah J.; Chan, Stephanie

doi:10.1016/s0029-6465(22)02695-0

Cited by 9 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efforts to develop innovative anti-obesity drugs have intensified recently, and a more appropriate, medically based outcome measure for obesity treatment has been advocated (Blackburn et al 1997). It is well established that weight loss in obese patients will lead to a significant amelioration in obesity-related disorders (Poirier et al 2006) and the reduction of caloric intake induces weight loss.…”

Section: Introductionmentioning

confidence: 99%

Dose response biology of resveratrol in obesity

Scapagnini

Davinelli

Kaneko

et al. 2014

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Obesity is a major health problem throughout the world, and it is increasing both in prevalence and severity. Pharmaceutical approaches developed for the treatment of obesity, despite short-term benefits, often are associated with rebound weight gain after the cessation of drug use and serious side effects deriving from the medication can occur. Resveratrol has been well recognized as an anti-obesity substance for its lipid-lowering function as well as calorierestriction effect. This polyphenol induces hormetic dose responses in a wide range of biological models, affecting numerous endpoints of biomedical and therapeutic significance. From an hormetic standpoint, we will discuss the potential relevance of resveratrol in the management of obesity and related comorbid conditions, emphasizing its ability to control simultaneously various pathological mechanisms associated with obesity.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose response biology of resveratrol in obesity

Scapagnini

Davinelli

Kaneko

et al. 2014

J. Cell Commun. Signal.

View full text Add to dashboard Cite

show abstract

“…4 So, it makes sense to consider weight loss as a way to enhance your health. 7 Every obesity therapy, but especially a drug's effectiveness, should be evaluated on the basis of something like this.…”

Section: Introductionmentioning

confidence: 99%

Revisiting the Most Successful United States Food and Drug Administration-approved Anti-obesity Drug Sibutramine sulfate: A Comprehensive Pharmacotherapeutic Review

Yadav¹,

Sahu²,

Agrawal³

et al. 2022

IJMPS

View full text Add to dashboard Cite

Introduction: Serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor sibutramine work together. Sibutramine primarily affects food intake and energy expenditure by way of its two pharmacologically active metabolites, primary and secondary amines, which cause significant weight loss. In addition to stimulating thermogenesis and enhancing the physiological process of satiety, it can also increase the efferent sympathetic activity to brown fat that is thermochemically active. Aim: Revisiting the Most Successful United States Food and Drug Administration-approved Anti-obesity Drug Sibutramine sulfate. Methodology: For a duration of 10 years, literature is covered. Results: Clinical studies using sibutramine show a dose-related decrease in body weight, with weight loss up to 11% below the baseline that can last up to 18 months with ongoing therapy. Patients assigned to the sibutramine medication continued to lose weight throughout a 1-year period, reaching 15% below baseline, while the patients receiving the placebo treatment had some weight increase when weight loss is induced with a very low-calorie diet (VLCDL). By lowering the biochemical risk factors for obesity, such as plasma triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, and insulin, and raising HDL cholesterol, sibutramine enhances metabolic fitness. Conclusion: Sibutramine has been shown to be a beneficial treatment for obese people with moderately high blood pressure, and it has even been shown to reduce blood pressure on average as a result of weight reduction. The potential for misuse that is associated with amphetamine is not present with sibutramine, and in investigations evaluating abuse potential, it is identical to placebo.

show abstract

Pharmacological Treatment of Obesity: Outcomes and New Tools

Campfield¹,

Fj²

2000

Obesity: Pathology and Therapy

View full text Add to dashboard Cite

Pharmaceutical Treatment of Obesity

Cited by 9 publications

References 33 publications

Dose response biology of resveratrol in obesity

Dose response biology of resveratrol in obesity

Revisiting the Most Successful United States Food and Drug Administration-approved Anti-obesity Drug Sibutramine sulfate: A Comprehensive Pharmacotherapeutic Review

Pharmacological Treatment of Obesity: Outcomes and New Tools

Contact Info

Product

Resources

About